How should we assess patient-reported outcomes in the onco-hematology clinic?

Purpose of review The improvement of clinical outcomes in hematologic malignancies has paved the way for a more systematic patient-reported outcomes (PROs) assessment in routine clinical practice. PROs help to narrow the gap between patients' and healthcare professionals' view of patient health and treatment success. This review outlines key aspects of planning and performing PRO assessments in daily routine such as the selection of PRO instruments, electronic PRO data collection, and the presentation and interpretation of PRO results. Recent findings A substantial body of literature has demonstrated that careful planning, adequate logistics, and elaborate methodology allow to successfully integrate the patients' experience in routine care. Several examples exist of the clinical benefits of systematically collecting PRO information in daily care of patients with solid tumors. These include improved patient–physician communication, better symptom management, and, in patients with advanced disease, also fewer hospitalizations and prolonged survival. However, sparse evidence based data are available for patients with onco-hematologic diseases. Summary Data collected through PRO instruments provide unique information that complements traditional clinical examinations and may help improving patients' management in clinical practice. Major efforts are now needed to implement PRO instruments in daily practice of patients with hematologic malignancies. Correspondence to Laura Cannella, MD, Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases (GIMEMA), GIMEMA Data Center, Via Benevento, 6, 00161 Rome, Italy. Tel: +39 06 441 639837; e-mail: l.cannella@gimema.it Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (https://ift.tt/2FWWEea). Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.

https://ift.tt/2MPHWFb